CD2 and melanoma: Several gene expression and immune monitoring studies conducted on clinical samples have reported that increased CD2 expression is correlated with improved survival rates in patients with melanoma, breast cancer, AML and diffuse large B-cell lymphoma (DLBCL)149–152.